Evidence map›Paper›PMID 25678954›Full record

ReviewTherapeutic advances in endocrinology and metabolism2015

Dapagliflozin in patients with type 2 diabetes mellitus.

Theodosios D Filippatos, Evangelos N Liberopoulos, Moses S Elisaf

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
    Review
  7. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes.Clinical pharmacology : advances and applications · 2019
    Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Theodosios D FilippatosAssistant Professor of Internal Medicine Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Evangelos N LiberopoulosAssistant Professor of Internal Medicine Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Moses S ElisafDepartment of Internal Medicine, School of Medicine, University of Ioannina, 45 110 Ioannina, Greece.
University of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dapagliflozin is a selective and reversible inhibitor of sodium-glucose linked transporter type 2 (SGLT2), which mediates approximately 90% of active renal glucose reabsorption in the early proximal tubule of the kidney. Dapagliflozin significantly reduces glucose reabsorption and decreases serum glucose concentration in an insulin-independent manner. The decrease of glucose reabsorption by dapagliflozin has also been associated with a reduction in body weight. Furthermore, the drug modestly reduces blood pressure levels through weight loss and its action as osmotic diuretic. Dapagliflozin has been approved as monotherapy in patients with type 2 diabetes mellitus (T2DM) who cannot tolerate metformin or in combination with other antidiabetic drugs, with the exception of pioglitazone due to the theoretical increased risk of bladder cancer. The drug should not be prescribed in patients with moderate or severe renal impairment or in patients at risk for developing volume depletion. Dapagliflozin is associated with increased incidence of genital and lower urinary tract infections, but these infections are usually mild to moderate and respond to standard antimicrobial treatment. Based on current evidence, dapagliflozin is a useful drug for patients with T2DM with a favorable safety profile. However, further research regarding the effects of dapagliflozin on cardiovascular outcomes is needed.

Indexed as

adverse effectsblood pressurebody weightdapagliflozindiabetes mellitusdrug interactionsmetabolic effectssodium–glucose linked transporter type 2 inhibitors

Identifiers

PMID25678954
PMCPMC4321869
OpenAlexW2114493476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.